The partner of choice for pharmaceutical companies
Bring game-changing drugs to market more efficiently. We’ll help you understand the competition to hone in on your strategies to improve healthcare and patient outcomes.
The right drugs developed at the right time transform pharmaceutical and biotechnology companies and improve patients’ lives. But the process is long and complex, taking place in an ever-changing, intensely competitive arena.
How we help
As the trusted pharma research partner of the top 50 global pharmaceutical companies, we provide reliable, timely intelligence and insights to help you every step of the way during drug development.
We can help you:
Key benefits:
Key benefits:
Biomedtracker, Scrip
Keep up with events as they unfold at the 39th Annual J.P. Morgan Annual Healthcare Conference on January 11-14, 2021. Pharma Intelligence and Insights journalists will bring you real time reporting, highlighting important events and key takeaways from every day of the largest and most informative healthcare investment symposium in the industry.
Scrip
Could Serum Institute or Bharat Biotech be the first company to have a COVID-19 vaccine for children under 12 years of age? While Pfizer and Moderna have begun pediatric trials for children 12 years and above, Serum plans to begin testing its indigenous vaccine and Bharat Biotech its Covaxin in children under 12
Topic Coronavirus
Scrip
Development of vaccines usually takes years, but drug makers whittled the process down to a matter of months amid a concerted response to a global health threat.
Topic Coronavirus
Citeline, Sitetrove, Trialtrove
Even one misstep in your clinical trials strategy or execution can cost your company millions. Save time and cost with the trusted source for global investigator and site intelligence and global pharmaceutical clinical trial intelligence by subscribing to Sitetrove and Trialtrove.
Topic Clinical Trials Coronavirus
Generics Bulletin
Reforms set out by the European Commission to better prepare the EU for future health crises must heed key lessons learned from experiences of the COVID-19 pandemic, such as the benefits of digitalization, Medicines for Europe has urged.
Topic Coronavirus EU Policy & Regulation
HBW Insight
A nasal spray formulated using compounds already approved by regulatory bodies in Europe and the US can “prevent and slow” transmission of COVID-19, according to UK researchers who are now seeking a partner to commercialize the product.
HBW Insight
Will the second wave of coronavirus lockdown have the same impact on the European consumer health industry? Speaking exclusively to HBW Insight from Germany, Merz Consumer Care CEO Frank Baldauf thinks not. Recently investing in premium beard care brand Brooklyn Soap and launching its tetesept Formula range in the Netherlands, Merz's Baldauf suggest that there will be less panic buying this time round and the CHC supply chain will hold up under pressure.
Topic Coronavirus OTC Drugs EU
Scrip
Join us for a brief audio tour around the past week's key developments in the global biopharma industry, in this podcast version of Scrip's Five Must-Know Things
Scrip
Russia is promising the best of both worlds – a low price with a near-perfect efficacy. While the basic science is plausible, its best-in-class claims are bound to generate skepticism
Topic Coronavirus Vaccines
Scrip
Oxford University/AstraZeneca’s COVID-19 vaccine cuts the spread of the virus by 60%, apart from having 70% efficacy in reducing infections in vaccinated individuals. While that is good news for their Indian partner, Serum Institute, the 90% efficacy shown in a subset due to a dosing error causes a dilemma.
Topic Coronavirus Vaccines
Scrip
As part of broader efforts to pursue novel approaches to common neurological disorders, Eisai uses iPSC-derived cells to help identify potential new drug therapies for Parkinson's.
Topic Parkinson's Disease
HBW Insight
IFRA’s new chairman Hans Holger Gliewe says one possible positive outcome of the COVID-19 pandemic could be that consumers go on putting a premium on scientific expertise after months of reliance on health experts’ advice.
Topic Coronavirus Cosmetics
Scrip
The latest figures from China's National Health Commission show infections of the new Wuhan coronavirus are continuing to pile up, spreading to more cities in the country and abroad as travel for the Lunar New Year festival goes into high gear. Meanwhile, the Chinese government maintains that the situation is “preventable and controllable.”
Topic China Infectious Diseases Policy & Regulation Coronavirus
HBW Insight
The COVID-19 pandemic has impacted the consumer health and beauty products industries in different ways, and HBW Insight covers it all. We deliver all the latest regulatory, legislative, legal and commercial developments across the over-the-counter medicine, dietary supplement and the cosmetics sectors to keep you informed and strategically on target.
Topic Coronavirus
Scrip
Janssen has returned the rights to an obesity/diabetes drug to originator Hanmi, after Phase II studies failed to achieve glycemic control targets and reflecting development difficulties in the sector. This is the fourth time for the Korean firm to face a U-turn of licensed out compounds.
HBW Insight
23 Jan 2021
HBW Insight
22 Jan 2021
HBW Insight
22 Jan 2021
Scrip
22 Jan 2021
Scrip
22 Jan 2021
HBW Insight
22 Jan 2021
Scrip
22 Jan 2021
Scrip
22 Jan 2021
Generics Bulletin
22 Jan 2021
HBW Insight
22 Jan 2021
Generics Bulletin
22 Jan 2021
Scrip
22 Jan 2021
Scrip
22 Jan 2021
HBW Insight
22 Jan 2021
HBW Insight
22 Jan 2021
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
Our team is always happy to hear from you. Please call us at:
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: